224 related articles for article (PubMed ID: 37246171)
1. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer.
Zhang S; Yao HF; Li H; Su T; Jiang SH; Wang H; Zhang ZG; Dong FY; Yang Q; Yang XM
Cell Oncol (Dordr); 2023 Oct; 46(5):1473-1492. PubMed ID: 37246171
[TBL] [Abstract][Full Text] [Related]
2. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling.
Wang F; Wang L; Qu C; Chen L; Geng Y; Cheng C; Yu S; Wang D; Yang L; Meng Z; Chen Z
BMC Cancer; 2021 Apr; 21(1):396. PubMed ID: 33845796
[TBL] [Abstract][Full Text] [Related]
3. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
[TBL] [Abstract][Full Text] [Related]
4. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
[TBL] [Abstract][Full Text] [Related]
5. TGM2: a cell surface marker in esophageal adenocarcinomas.
Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.
Malkomes P; Lunger I; Oppermann E; Lorenz J; Faqar-Uz-Zaman SF; Han J; Bothur S; Ziegler P; Bankov K; Wild P; Bechstein WO; Rieger MA
Cancer Gene Ther; 2023 Oct; 30(10):1346-1354. PubMed ID: 37443286
[TBL] [Abstract][Full Text] [Related]
7. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
8. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
9. TGM2 and implications for human disease: role of alternative splicing.
Lai TS; Greenberg CS
Front Biosci (Landmark Ed); 2013 Jan; 18(2):504-19. PubMed ID: 23276939
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
11. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Park KS; Kim HK; Lee JH; Choi YB; Park SY; Yang SH; Kim SY; Hong KM
J Cancer Res Clin Oncol; 2010 Apr; 136(4):493-502. PubMed ID: 19763620
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
14. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Agnihotri N; Kumar S; Mehta K
Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles.
Yamaguchi H; Kuroda K; Sugitani M; Takayama T; Hasegawa K; Esumi M
Int J Oncol; 2017 May; 50(5):1749-1759. PubMed ID: 28339069
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes.
Hallstrand TS; Wurfel MM; Lai Y; Ni Z; Gelb MH; Altemeier WA; Beyer RP; Aitken ML; Henderson WR
PLoS One; 2010 Jan; 5(1):e8583. PubMed ID: 20052409
[TBL] [Abstract][Full Text] [Related]
17. The transglutaminase 2 gene is aberrantly hypermethylated in glioma.
Dyer LM; Schooler KP; Ai L; Klop C; Qiu J; Robertson KD; Brown KD
J Neurooncol; 2011 Feb; 101(3):429-40. PubMed ID: 20596752
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.
Yin J; Oh YT; Kim JY; Kim SS; Choi E; Kim TH; Hong JH; Chang N; Cho HJ; Sa JK; Kim JC; Kwon HJ; Park S; Lin W; Nakano I; Gwak HS; Yoo H; Lee SH; Lee J; Kim JH; Kim SY; Nam DH; Park MJ; Park JB
Cancer Res; 2017 Sep; 77(18):4973-4984. PubMed ID: 28754668
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
Yeo SY; Itahana Y; Guo AK; Han R; Iwamoto K; Nguyen HT; Bao Y; Kleiber K; Wu YJ; Bay BH; Voorhoeve M; Itahana K
Elife; 2016 Mar; 5():e07101. PubMed ID: 26956429
[TBL] [Abstract][Full Text] [Related]
20. The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
Mohammadzadeh Z; Omidkhoda A; Chahardouli B; Hoseinzadeh G; Moghaddam KA; Mousavi SA; Rostami S
BMC Cancer; 2021 Jan; 21(1):46. PubMed ID: 33422029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
